Better diagnostics, better treatment
Saving lives through antibiotic sensitivity precision diagnosticsSolution
At Astek Diagnostics, we are creating the JIDDU system, an innovative clinical diagnostics platform that offers infection confirmation for urinary tract infections (UTIs) and antibiotic sensitivity indication within 1 hour.
The JIDDU system greatly improves diagnostic speed and accuracy, thereby reducing patient complications and pain, as well as lowering healthcare costs. It represents a significant leap forward in patient care that allows for much more timely and accurate treatment than the current standard of care. This ultimately leads to saving lives, given that 25% of sepsis cases are caused by UTIs.
Given that women get UTIs up to 30 times more often than men, the development and deployment of the JIDDU system would have major implications on FemHealth.
UTIs are among the leading precursors of antimicrobial resistance (AMR)
AMR is among the biggest global health threatsProblem
A leap forward from the current “gold standard” of UTI diagnostics and treatment
Rapid and actionable results within 1 hourSolution
Going beyond UTI diagnostics and treatment
Developing a universal diagnostic system which tests 4 sample typesGrand vision
How it started
Mustafa Al Adhami, PhD
CEO at Astek Diagnostics
In 2021, the growing issue of antibiotic resistant UTIs became personal for Mustafa. His grandfather was suffered from agonizing pain for days before being diagnosed with a UTI and being treated with the right antibiotic. Mustafa’s family felt entirely helpless during this experience.
Recognizing the need for a solution, Mustafa founded Astek Diagnostics. Ever since, he has been dedicated to revolutionizing the way antibiotics are prescribed to patients.
Today, in partnership with key healthcare institutions such, including The University of Maryland Medical Center and MedStar Health, Astek Diagnostics has achieved exceptional initial results and is well on its way to a market entry in 2025.